|Bid||16.11 x 800|
|Ask||16.68 x 1400|
|Day's Range||16.16 - 16.94|
|52 Week Range||15.18 - 35.48|
|Beta (3Y Monthly)||1.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.63|
DUBLIN, June 18, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today reported new data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) in patients with neurogenic orthostatic hypotension (nOH) in a poster presentation at the 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress. New data demonstrated that the study's previously reported improvements in nOH symptom severity following four weeks of treatment were sustained until the completion of 20 weeks of ampreloxetine therapy.
Theravance Biopharma Inc NASDAQ NMS:TBPHView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for TBPH with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding TBPH are favorable, with net inflows of $2.64 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Statistically speaking, long term investing is a profitable endeavour. But no-one is immune from buying too high...
For biotech stocks, the week was back loaded with multiple conferences scheduled for the later half of the week. Nevertheless, there were volatile moves in some low-float, thinly traded stocks. Looking ...
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, June 14, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced the expansion of the companies' current development and commercialization agreement for nebulized revefenacin to include China and certain adjacent territories. Revefenacin, marketed as YUPELRI® in the U.S., is a long-acting muscarinic antagonist (LAMA), which is the first and only once-daily, nebulized bronchodilator approved for the treatment of chronic obstructive pulmonary disease (COPD) in the U.S.
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Experienced Life Science Industry Executive with Strong Track Record of Long-Term Value Creation and Broad Therapeutic Expertise DUBLIN , June 4, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: ...
Numerically higher rates of clinical response were observed for TD-1473 after four weeks of treatment as compared to placebo. Clinical response, which was defined as a reduction in total Mayo score of ≥ 3 points and ≥ 30%, with a reduction in rectal bleeding subscore by ≥ 1 point or an absolute rectal bleeding subscore of ≤ 1 point, was achieved by 2 of 10 patients (20%) in the 20 mg cohort, 2 of 10 patients (20%) in the 80 mg cohort, and 6 of 11 patients (55%) in the 270 mg cohort, compared to 1 of 9 patients (11%) in placebo group.
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, May 20, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-week safety study at the 2019 American Thoracic Society (ATS) International Conference in Dallas, Texas. YUPELRI® (revefenacin) inhalation solution, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in the U.S.
DUBLIN, May 14, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that results from the Company's Phase 1b study of TD-1473 in patients with moderately-to-severely active ulcerative colitis will be the focus of an oral presentation at Digestive Disease Week (DDW) 2019. The presentation will highlight final data from the Phase 1b clinical trial of TD-1473 in patients with moderately-to-severely active ulcerative colitis. These findings demonstrate signals of clinical and biomarker activity for TD-1473 suggesting localized target engagement, as well as minimal systemic exposure and no evidence of systemic immunosuppression or infections. DDW 2019 is being held May 18-21, 2019 in San Diego, CA.
Theravance Biopharma (TBPH) retains its earlier issued guidance for 2019 operating loss sans non-cash share-based compensation in the range of $210-$230 million.
Theravance Bio (TBPH) delivered earnings and revenue surprises of -11.86% and -67.54%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the George Town, Cayman Islands-based company said it had a loss of $1.32. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- Late-stage clinical studies of TD-1473 and ampreloxetine underway - Phase 1 results including biomarker data in asthmatics for lung-selective inhaled pan-JAK inhibitor TD-8236 expected in third quarter ...
How do we determine whether Theravance Biopharma Inc (NASDAQ:TBPH) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
DUBLIN, Ireland, April 30, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended March 31, 2019 and provide a business update after market close on Tuesday, May 7, 2019. To participate in the live call by telephone, please dial (855) 296-9648 from the US, or (920) 663-6266 for international callers, using the confirmation code 9890346. A replay of the conference call will be available on Theravance Biopharma's website for 30 days through June 6, 2019.